MA42508B1 - Dérivés d'éthynyle - Google Patents

Dérivés d'éthynyle

Info

Publication number
MA42508B1
MA42508B1 MA42508A MA42508A MA42508B1 MA 42508 B1 MA42508 B1 MA 42508B1 MA 42508 A MA42508 A MA 42508A MA 42508 A MA42508 A MA 42508A MA 42508 B1 MA42508 B1 MA 42508B1
Authority
MA
Morocco
Prior art keywords
ethynyl derivatives
disease
formula
gerd
anxiety
Prior art date
Application number
MA42508A
Other languages
English (en)
Inventor
Eric Vieira
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA42508B1 publication Critical patent/MA42508B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C11/00—Aliphatic unsaturated hydrocarbons
    • C07C11/22—Aliphatic unsaturated hydrocarbons containing carbon-to-carbon triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés d'éthynyle de formule (i) dans laquelle r1 représente un hydrogène ou f ; n représente 1 ou 2 ou un sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci. De manière surprenante, il s'est avéré que les composés de formule générale (i) sont des antagonistes du récepteur métabotropique du glutamate (modulateurs allostériques négatifs) destinés à être utilisés dans le traitement de l'anxiété et de la douleur, de la dépression, du syndrome de l'x fragile, des troubles du spectre autistique, de la maladie de parkinson et du reflux gastro-œsophagien pathologique (gerd).
MA42508A 2015-06-03 2016-05-31 Dérivés d'éthynyle MA42508B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170401 2015-06-03
PCT/EP2016/062202 WO2016193234A1 (fr) 2015-06-03 2016-05-31 Dérivés d'éthynyle

Publications (1)

Publication Number Publication Date
MA42508B1 true MA42508B1 (fr) 2020-05-29

Family

ID=53276789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42508A MA42508B1 (fr) 2015-06-03 2016-05-31 Dérivés d'éthynyle

Country Status (30)

Country Link
US (2) US11059766B2 (fr)
EP (1) EP3303316B1 (fr)
JP (1) JP6603334B2 (fr)
KR (1) KR102035048B1 (fr)
CN (1) CN107849006B (fr)
AR (1) AR104842A1 (fr)
AU (1) AU2016273751B2 (fr)
BR (1) BR112017023894A2 (fr)
CA (1) CA2985301A1 (fr)
CL (1) CL2017002969A1 (fr)
CO (1) CO2017012260A2 (fr)
CR (1) CR20170536A (fr)
DK (1) DK3303316T3 (fr)
ES (1) ES2786673T3 (fr)
HR (1) HRP20200638T1 (fr)
HU (1) HUE048867T2 (fr)
IL (1) IL255367B (fr)
LT (1) LT3303316T (fr)
MA (1) MA42508B1 (fr)
MX (1) MX378334B (fr)
PE (1) PE20180358A1 (fr)
PH (1) PH12017502128A1 (fr)
PL (1) PL3303316T3 (fr)
PT (1) PT3303316T (fr)
RS (1) RS60199B1 (fr)
RU (1) RU2712633C1 (fr)
SI (1) SI3303316T1 (fr)
TW (1) TWI589571B (fr)
UA (1) UA120309C2 (fr)
WO (1) WO2016193234A1 (fr)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549655A (en) * 1967-12-21 1970-12-22 Dow Chemical Co N-(substituted phenyl) cyclobutanedicarboximides
FI90869C (fi) 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
JP3213780B2 (ja) 1993-12-21 2001-10-02 キヤノン株式会社 光学活性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置
GB9510744D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
JPH09151179A (ja) 1995-11-30 1997-06-10 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた液晶装置及び表示方法
ID29095A (id) 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
JP4815083B2 (ja) 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
NZ517788A (en) 1999-09-28 2003-11-28 Eisai Co Ltd Quinuclidine compounds and drugs containing the same as the active ingredient
WO2002014517A1 (fr) 2000-08-11 2002-02-21 Monsanto Technology Llc $g(d)-endotoxines a large spectre
US6410728B1 (en) 2000-08-31 2002-06-25 Abbott Laboratories Oxazolidinone chemotherapeutic agents
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
DE60220997T2 (de) 2001-03-27 2008-03-13 Eisai R&D Management Co., Ltd. N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
DE60214846T2 (de) 2001-04-02 2007-05-16 Brown University Research Foundation Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
JP2006513996A (ja) 2002-10-24 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
DE602005017129D1 (de) 2004-03-22 2009-11-26 Lilly Co Eli Pyridyl-derivate und ihre verwendung als mglu5-rezeptorantagonisten
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
CA2583572C (fr) 2004-10-07 2016-07-12 Merck & Co., Inc. Antagonistes du glutamate mglur5 de thiazolyle et methodes d'utilisation
WO2006048771A1 (fr) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0514296D0 (en) 2005-07-12 2005-08-17 Novartis Ag Organic compounds
KR20080034944A (ko) 2005-08-19 2008-04-22 아스트라제네카 아베 결핵 치료용 피라졸론 유도체
WO2007035823A2 (fr) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Antagonistes partiels de mglur5 et leurs méthodes d'utilisation
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
EP2240476A1 (fr) 2008-02-05 2010-10-20 NeuroSearch A/S Nouveaux dérivés phényléthynylés de 8-azabicyclo[3.2.1]octane et leur utilisation comme inhibiteurs de la réabsorption d'un neurotransmetteur monoamine
WO2010063487A1 (fr) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
KR101862626B1 (ko) 2010-07-09 2018-05-31 레코르다티 아일랜드 리미티드 Mglu5 대항체로서의 신 스피로헤테로사이클릭 화합물
EP2599775A4 (fr) 2010-07-29 2014-04-30 Taisho Pharmaceutical Co Ltd Dérivé d'éthinyl-pyrazole
US8691821B2 (en) 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
HRP20150555T1 (hr) * 2011-04-26 2015-07-03 F. Hoffmann - La Roche Ag Derivati etinila kao pozitivni alosterijski modulatori za mglur5
EP2702050B1 (fr) 2011-04-26 2016-05-18 F.Hoffmann-La Roche Ag Dérivés de pyrazolidine-3-one
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
AU2013292142B2 (en) * 2012-07-17 2017-03-09 F. Hoffmann-La Roche Ag Arylethynyl derivatives
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
EP2900659B1 (fr) * 2012-09-27 2016-08-24 F. Hoffmann-La Roche AG Dérivés d'aryléthynyle
WO2014060398A1 (fr) * 2012-10-18 2014-04-24 F. Hoffmann-La Roche Ag Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
MY171517A (en) 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
HUE041392T2 (hu) 2014-02-25 2019-05-28 Hoffmann La Roche Etinil származékok

Also Published As

Publication number Publication date
IL255367A0 (en) 2017-12-31
US11059766B2 (en) 2021-07-13
CA2985301A1 (fr) 2016-12-08
WO2016193234A1 (fr) 2016-12-08
TWI589571B (zh) 2017-07-01
EP3303316A1 (fr) 2018-04-11
AR104842A1 (es) 2017-08-16
CN107849006A (zh) 2018-03-27
US12195413B2 (en) 2025-01-14
LT3303316T (lt) 2020-05-11
KR102035048B1 (ko) 2019-10-22
HK1249096A1 (zh) 2018-10-26
PE20180358A1 (es) 2018-02-21
RU2712633C1 (ru) 2020-01-30
RS60199B1 (sr) 2020-06-30
ES2786673T3 (es) 2020-10-13
EP3303316B1 (fr) 2020-01-29
HRP20200638T1 (hr) 2020-07-10
CO2017012260A2 (es) 2018-03-28
CN107849006B (zh) 2020-11-13
PH12017502128A1 (en) 2018-05-28
US20180086680A1 (en) 2018-03-29
DK3303316T3 (da) 2020-04-27
KR20180004821A (ko) 2018-01-12
BR112017023894A2 (pt) 2018-07-17
IL255367B (en) 2021-02-28
MX378334B (es) 2025-03-10
PT3303316T (pt) 2020-04-27
HUE048867T2 (hu) 2020-08-28
SI3303316T1 (sl) 2020-07-31
PL3303316T3 (pl) 2020-06-29
AU2016273751B2 (en) 2020-04-02
TW201708204A (zh) 2017-03-01
JP2018517695A (ja) 2018-07-05
MX2017015043A (es) 2018-02-26
JP6603334B2 (ja) 2019-11-06
UA120309C2 (uk) 2019-11-11
US20210300844A1 (en) 2021-09-30
CL2017002969A1 (es) 2018-04-13
CR20170536A (es) 2018-02-01
AU2016273751A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
EA200801934A1 (ru) 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
MA38217A1 (fr) Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2
MA38659B1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MA38011B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5
EA201590676A1 (ru) Производные этинила в качестве модуляторов активности рецептора mglur5
MA42508B1 (fr) Dérivés d'éthynyle
EA201290532A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов рецепторов mglur5
MA37895A1 (fr) Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité
MA34200B1 (fr) Dérivés de pyrimidine condensée en tant que modulateurs de trpv3
TN2010000612A1 (fr) Derives de triazole utiles pour le traitement de maladie